SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026GuruFocus · Oct 17, 2026
Chesapeake Utilities Corporation (NYSE:CPK) Stock Rated “Moderate Buy” by Wall Street AnalystsDefense World · Oct 6, 2026
CHESAPEAKE UTILITIES CORPORATION ANNOUNCES $225 MILLION AT-THE-MARKET (ATM) EQUITY OFFERING PROGRAMPRNewsWire · Oct 1, 2026
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressGuruFocus · Sep 30, 2026
50,451 Shares of Chesapeake Utilities Corporation $CPK Acquired by Bank of America Corp DEDefense World · Sep 28, 2026
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisGuruFocus · Sep 22, 2026Chesapeake Utilities Corporation (CPK) operates as a diversified energy enterprise, delivering a range of energy solutions to its customers. The company's operations are distinctly divided into two primary segments: Regulated Energy and Unregulated Energy. The Regulated Energy division manages essential utility services, which include the distribution of natural gas across central and southern Delaware, Maryland's eastern shore, and various parts of Florida.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $1.07 | $1.05 | Miss |
| May 6, 2026 | $2.38 | $2.47 | Beat |
| Feb 25, 2026 | $1.94 | $1.94 | Beat |
| Nov 6, 2025 | $0.90 | $0.82 | Miss |
| Aug 7, 2025 | $1.00 | $1.04 | Beat |
| May 7, 2025 | $2.28 | $2.22 | Miss |